FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 445 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο February 22, 2020 Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 Whole-Genome Sequencing Could Help Guide AML Treatment April 6, 2021 Load more HOT NEWS News digest – ovarian cancer blood test, statins, spending review and... Intensive care nurse describes his experience of female-centred care after breast... ΜΥΘΟΙ ΚΑΙ ΑΛΗΘΕΙΕΣ Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early...
